Ron Derosa

Territory Manager/ Field Sales Trainer

Role: Field Sales Trainer at Intrinsic Therapeutics, Inc
Location: Chicago, IL, US
LinkedIn followers: 500 followers

Sales & Business DevelopmentView LinkedIn profile

About Ron Derosa

Results-driven Sales Leader and Business Consultant with 10 years of experience in the healthcare market, specializing in disruptive technologies. Proven track record as a revenue generator in complex markets, consistently surpassing annual sales quotas. Skilled in building rapport with key customers and driving pipeline growth. Strong background in training and mentoring field sales teams.

Experience

Field Sales Trainer
Intrinsic Therapeutics, Inc
Jan 2024 — Present · Chicago, IL, US
Experienced field trainer specializing in field training of new hires. Additionally responsible for leading and supporting national meetings, training classes and area meetings. Collaborating with the VP of National Field Integration to integrate strategic business imperatives. Actively participate in NHT, Advance Training, NSM, NTM, and Subject Matter Expert panels while sharing best practices with the national FST team.

Education

Saint John's University
B.S., Advertising
2010 — 2012

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@barricaid.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Intrinsic Therapeutics, Inc

Medical Equipment Manufacturing · 91 employees · Founded 2000 · Woburn, Massachusetts, United States

Adjacent to a lumbar discectomy, the Barricaid® device is designed to close large defects in the annulus, which often lead to disc reherniation and/or disc collapse. Barricaid is a permanent implant with two components - a titanium bone anchor and a flexible polymer barrier. The barrier is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect. The anchor component is comprised of titanium alloy that is placed into either the caudal or cranial-adjacent vertebral body to secure the device in position. The Barricaid has been studied in a definitive – level 1B evidence - randomized superiority trial with over 550 patients enrolled (clinicaltrials.gov NCT01••••38). The study focuses on patient at highest risk of reherniation and reoperation, enrolling only those patients with large defects (width >5 mm). The co-primary endpoints of reherniation and an 8-point composite of safety and effectiveness are evaluated at 2 years, with a parallel cost effectiveness analysis. Treated patients were found superior on both endpoints, with significantly lower rates of symptomatic recurrences (12% vs. 25%, p<0.001), index-level reoperations (9% vs. 16%, p=0.01), and device or procedure related serious adverse events (SAEs)(7% vs. 17%, p=0.001). Through two years, a total of 29 reoperations were performed in Barricaid subjects in comparison to 61 procedures in Controls. Study results are published in The Spine Journal, May 2018. Barricaid is FDA-Approved For full risk/benefit, see:

barricaid.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Ron Derosa

Experience

Field Sales Trainer

Education

Saint John's University

Find verified contacts for anyone on LinkedIn